Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs

Journal of Veterinary Internal Medicine

Volumn 21, Issue 4, 2007, Pages 764-769

  Lana, Susan ^a   U'ren, Lance ^a   Plaza, Susan ^a   Elmslie, Robyn ^b   Gustafson, Daniel ^c   Morley, Paul ^a   Dow, Steven ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Health Sciences Center ^*

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Cyclophosphamide; Doxorubicin; Etoposide; Piroxicam; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; ETOPOSIDE;

ANGIOSARCOMA; ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; FEMALE; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SPLEEN TUMOR;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; DOXORUBICIN; ETOPOSIDE; FEMALE; HEMANGIOSARCOMA; MALE; SPLENIC NEOPLASMS;

ANIMALIA; CANIS FAMILIARIS;

EID: 34547818190     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2007)21[764:CLOCFA]2.0.CO;2     Document Type: Article

References (37)

1. Clifford CA, Mackin AJ, Henry CJ. Treatment of canine hemangiosarcoma: 2000 and beyond. J Vet Intern Med 2000;14: 479-485.
2. Brown NO. Hemangiosarcomas. Vet Clin North Am Small Anim Pract 1985;15:569-575.
3. Smith AN. Hemangiosarcoma in dogs and cats. Vet Clin North Am Small Anim Pract 2003;33:533-552, vi.
4. Wood CA, Moore AS, Gliatto JM, et al. Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991-1993). J Am Anim Hosp Assoc 1998;34: 417-421.
5. Ogilvie GK, Powers BE, Mallinckrodt CH, et al. Surgery and doxorubicin in dogs with hemangiosarcoma. J Vet Intern Med 1996;10:379-384.
6. Sorenmo KU, Jeglum KA, Helfand SC. Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. J Vet Intern Med 1993;7:370-376.
7. Sorenmo KU, Baez JL, Clifford CA, et al. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma. J Vet Intern Med 2004;18:209-213.
8. Sorenmo K, Duda L, Barber L, et al. Canine hemangiosarcoma treated with standard chemotherapy and minocycline. J Vet Intern Med 2000;14:395-398.
9. Vail DM, MacEwen EG, Kurzman ID, et al. Liposomeencapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res 1995;1:1165-1170.
10. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
11. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436.
12. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-1206.
13. Munoz R, Shaked Y, Bertolini F, et al. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy, Breast 2005;14:466-479.
14. Shaked Y, Emmenegger U, Man S, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005;106:3058-3061.
15. Shaked Y, Emmenegger U, Francia G, et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 2005;65:7045-7051,
16. Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108:452-459.
17. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003;63:4342-4346.
18. Bocci G, Francia G, Man S, et al. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 2003;100:12917-12922.
19. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer, J Pediatr Hematol Oncol 2005;27:573-581.
20. Kieran MW. Anti-angiogenic therapy in pediatric neurooncology. J Neurooncol 2005;75:327-334.
21. Ashley DM, Meier L, Kerby T, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 1996;14:1922-1927.
22. Hohenhaus AE, Matus RE. Etoposide (VP-16). Retrospective analysis of treatment in 13 dogs with lymphoma. J Vet Intern Med 1990;4:239-241.
23. Ogilvie GK, Cockburn CA, Tranquilli WJ, et al. Hypotension and cutaneous reactions associated with intravenous administration of etoposide in the dog. Am J Vet Res 1988;49:1367-1370.
24. Knapp DW, Richardson RC, Chan TC, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.
25. Knapp DW, Glickman NW, Mohammed SI, et al. Antitumor effects of Piroxicam in spontaneous canine invasive urinary bladder cancer, a relevant model of human invasive bladder cancer. Adv Exp Med Biol 2002;507:377-380.
26. Henry CJ, McCaw DL, Turnquist SE, et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin Cancer Res 2003;9:906-911.
27. Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356-358.
28. Mutsaers AJ, Glickman NW, DeNicola DB, et al. Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs. J Am Vet Med Assoc 2002;220:1813-1817.
29. Boria PA, Murry DJ, Bennett PF, et al. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2004;224:388-394.
30. Qiu ZF, Maruyama K, Sunayama K, et al. Piroxicaminduced regression of intestinal adenomatous polyps in APC (delta474) mice. J Invest Surg 2003;16:71-81.
31. Salcedo R, Zhang X, Young HA, et al. Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood 2003;102:1966-1977.
32. Pang S, Zheng N, Felix CA, et al. Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. J Mass Spectrom 2001;36:771-781.
33. Glode LM, Barqawi A, Crighton F, et al. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003;98:1643-1648.
34. Charney SC, Bergman PJ, Hohenhaus AE, et al. Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990-1996). J Am Vet Med Assoc 2003;222:1388-1393.
35. Ogilvie GK, Reynolds HA, Richardson RC, et al. Phase II evaluation of doxorubicin for treatment of various canine neoplasms. J Am Vet Med Assoc 1989;195:1580-1583.
36. Thamm DH, Dickerson EB, Akhtar N, et al, Biological and molecular characterization of a canine hemangiosarcoma-derived cell line. Res Vet Sei 2006;81:76-86.
37. U'Ren LW, Biller BJ, Elmslie RE, Thamm D, Dow SW. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med 2007;21:113-120.